<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219468">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226954</url>
  </required_header>
  <id_info>
    <org_study_id>PROS0001</org_study_id>
    <secondary_id>78869</secondary_id>
    <secondary_id>PROS0001</secondary_id>
    <nct_id>NCT00226954</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer</brief_title>
  <official_title>Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Primary:

      To determine the duration of use of zoledronic acid in improving Bone mineral density in
      patients with prostate cancer who are on hormones intermittently.

      Secondary Objectives:

      To describe the safety and tolerability at this dose and schedule
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the safety and tolerability at this dose and schedule</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Urologic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients: Who are 18 years of age and older Who have histologically
        documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS
        greater than 80%Life expectancy greater than 6 months Provide written consent pursuant to
        regulatory requirements prior to initiation of study procedure

        Exclusion Criteria:Exclusion Criteria: Patients: Any patient requiring continuous LHRH Any
        patient who has had an orchiectomy Any patient with painful bone metastases Who have
        received chemotherapy for prostate cancer Who have a abnormal serum creatine &gt;2.5
        Receiving any investigational drug within the last 28 days Severe uncontrolled infection,
        diabetes, cardiac disease Patients with fragility fractures, hyperparathyroidism, Pagets
        renal osteodystrophy will be excluded History of non compliance to medical regimens or
        unwillingness to return for medical visits
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sandy Srinivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <lastchanged_date>July 27, 2009</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Dr. Sandy Srinivas, Principal Investigator</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
